
Browsing restrictions can be lifted for a fee.
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. Genovate Biotechnology Co., Ltd. was founded in 1982 and is based in Hsinchu City, Taiwan.
4130
健亞
4.22%
(0.04)
The most recent financial report for 健亞 (4130) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4130's short-term business performance and financial health. For the latest updates on 4130's earnings releases, visit this page regularly.
According to historical valuation range analysis, 健亞 (4130)'s current price-to-earnings (P/E) ratio is 236.54, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 健亞 (4130) reported an Operating Profit of -6.53M with an Operating Margin of -5.47% this period, representing a growth of 25.76% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 健亞 (4130) announced revenue of 119.4M, with a Year-Over-Year growth rate of 1%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 健亞 (4130) held Total Cash and Cash Equivalents of 169.04M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 健亞 (4130) did not achieve the “three margins increasing” benchmark, with a gross margin of 34%%, operating margin of -5.47%%, and net margin of -3.13%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4130's profit trajectory and future growth potential.
According to the past four quarterly reports, 健亞 (4130)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.03. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
健亞 (4130)'s Free Cash Flow (FCF) for the period is 3.18M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 60.74% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.